Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners drug formulary Coverage & PA | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    HealthPartners Formulary (2026)

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the HealthPartners 2026 drug formulary, describing covered medicines, pharmacy benefit rules (prior authorization, step therapy, quantity limits, age limits), specialty drug handling, and usage guidance for plan members and providers.

    Policy Summary
    PayerHealthPartners
    PolicyHealthPartners Formulary (2026)
    Policy CodePolicy N/A
    Change TypeMinor — no material changes
    Effective DateFeb 1, 2026
    Next Review DateMay 1, 2026
    Key ActionObtain prior authorization when the formulary entry for a medicine lists PA to ensure coverage and avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026Formulary year
    QuarterlyReview frequency
    RequiredSpecialty pharmacy
    MultiplePrior authorization entries
    20+Distinct entries (excerpt)

    Coverage Criteria & General Rules

    General coverage requirements

    Coverage is subject to plan rules and formulary edits; many drugs are covered only when specific conditions are met.

    Prior Authorization: Drug is covered when prior authorization criteria specific to the medication and the plan are met

    PA required for listed products per formulary entries

    Step Therapy: Coverage at preferred cost share requires trial and failure of specified first-line agents when ST applies

    ST entries are noted on the drug list; prior approval required if required alternatives have not been tried

    Quantity Limits: Coverage for quantities above QL requires medical necessity review including diagnosis, alternatives tried, prior use, and evidence of efficacy/safetyQL values vary by product
    Policy Summary
    PayerHealthPartners
    PolicyHealthPartners Formulary (2026)
    Policy CodePolicy N/A
    Change TypeMinor — no material changes
    Effective DateFeb 1, 2026
    Next Review DateMay 1, 2026
    Key ActionObtain prior authorization when the formulary entry for a medicine lists PA to ensure coverage and avoid claim denial.
    SourceLink
    On This Page
    Coverage Criteria & General RulesProvider Requirements, Authorization & Denial RisksFormulary Entries, Codes & ExamplesQuantity Limits (QL) — Specific ExamplesStep Therapy / Therapeutic DirectionSpecialty Pharmacy & Site RestrictionsTerminology & AbbreviationsBackground & ScopeRevision History

    Examples: nystatin oral suspension QL = 480 per 30 days; VIVJOA QL = 18 per 84 days

    Over-the-counter (OTC) drugs are generally not covered under the pharmacy benefit unless the formulary explicitly states otherwise. Members or prescribers should confirm plan-specific coverage and any formulary notations before expecting coverage for OTC products.

    The provided excerpt does not list explicit clinical exclusions. Instead, the formulary table emphasizes per-product management flags and tier assignments (for example, PA, ONC, S, TD, and QL) that govern coverage and utilization rather than broad clinical exclusion statements.

    When a product has an Age Limit (AL) edit, coverage is limited to members within the specified age range. If the patient is outside the approved age range, the member or prescriber must request prior approval from HealthPartners; coverage is not automatic for ages outside the approved range.

    Within this document excerpt there are no specific entries labeled as universally "not medically necessary." Coverage determinations instead rely on the drug-level requirement flags (such as PA, QL, ST, S) and clinical criteria associated with each formulary line to determine medical necessity.

    Provider Requirements, Authorization & Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization (PA) is required for many drugs listed in the formulary. Even when a medicine appears on the drug list, coverage under HealthPartners pharmacy benefits may be contingent on meeting PA criteria; if PA is not obtained the drug may not be covered.

    • PA is used to confirm coverage criteria are met for plan benefits.
    • When a product line shows the PA flag, providers must submit a prior authorization request before the drug will be covered at the plan’s preferred cost share.
    • Failure to obtain PA may result in the claim being denied or the drug not being covered.
    Step Therapy

    Step Therapy Requirement

    Step therapy (ST) requires that specified alternative agents be tried first. If the required prior treatments have not been tried, a prior approval (or PA) is required before the requested medicine will be covered at the preferred copay/coinsurance.

    • HealthPartners covers a step-therapy medicine only after required alternative(s) have been tried and documented.
    • If step therapy is not completed, submit clinical rationale and prior authorization evidence to request coverage.
    • Step/Program flags in the formulary indicate where ST applies and may trigger enhanced review.
    Denial Risk

    Requirements, Quantity Limits & Denial Triggers

    Quantity limits (QL), specialty (S), non-preferred (NP), oncology (ONC), opioid program (OP), enhanced (ENH) and other utilization flags on formulary lines can trigger additional review or denial if the requirements are not met.

    • Requests above a listed QL will be reviewed for medical necessity and require documentation of diagnosis, alternatives tried, prior use, and evidence supporting the quantity requested.
    • Many specialty and oncology agents are flagged S and/or ONC; absence of required specialty designation or PA may lead to denial.
    • NP/OP/TD/ENH flags indicate program edits or enhanced review that may require additional documentation or PA.
    • Exceeding QL or lacking required PA/NP/S documentation increases the risk of claim denial.
    Documentation Required

    Documentation Expectations and Required Information

    Provide supporting documentation with PA, QL exception, or step therapy override requests. Documentation should include diagnosis, prior therapies tried (dates and outcomes), dosing, pack size, quantity requested, and clinical rationale or evidence of efficacy and safety.

    • Requests above a QL: include diagnosis, alternatives tried, previous use within QL, and evidence supporting requested quantity.
    • For PA on oncology or specialty drugs: include oncology-specific documentation and any program-specific criteria referenced on the formulary line.
    • When ST is applied: document prior medication trials and reasons for failure/intolerance.
    • Age limits (AL) and other enrollment flags must be addressed in the documentation (e.g., Min 12 Years, Min 18 Years where noted).
    Note

    Examples of PA-Listed Drugs and Common PA Triggers

    Examples: numerous formulary entries show PA and related flags. Common examples include oncology and specialty oral agents (e.g., IBRANCE, VENCLEXTA, HARVONI, EPCLUSA), many antiepileptic medications (e.g., KEPPRA, NEURONTIN, ONFI), and multiple other agents across therapeutic classes. Review the formulary lines for PA, QL, S, NP, ONC, TD, and other flags.

    • Formulary lines explicitly list PA and other requirement flags next to each presentation — check the Requirements / Limits column when prescribing.
    • Some products additionally require specialty designation (S) and have specific QL entries (e.g., IBRANCE QL 21 per 28 days; VENCLEXTA QL per day and per 135 days).
    • Antiepileptic and many high-cost agents frequently show PA and QL; prescribers must submit PA and supporting documentation for these classes.

    Formulary Entries, Codes & Examples

    Formulary drug entries (sample)mixed
    ANCOBON ORAL CAPSULE 250 MG, 500 MGDrug Tier = NF; Requirements / Limits = PA
    BREXAFEMME ORAL TABLET 150 MGDrug Tier = NF; Requirements / Limits = PA
    clotrimazole mucous membrane troche 10 mgDrug Tier = 2
    CRESEMBA ORAL CAPSULE 186 MG, 74.5 MGDrug Tier = 3; Requirements / Limits = PA; NP
    fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/mlDrug Tier = 2
    nystatin oral suspension 100,000 unit/mlDrug Tier = 2; Requirements / Limits = QL (480 per 30 days)
    VIVJOA ORAL CAPSULE 150 MGDrug Tier = NF; Requirements / Limits = PA; QL (18 per 84 days)
    EPCLUSA ORAL TABLET 200-50 MGDrug Tier = 3; Requirements / Limits = PA; S
    HARVONI ORAL TABLET 45-200 MGDrug Tier = 3; Requirements / Limits = PA; S
    Quantity limit examplesmixed
    QL (21 per 28 days)Quantity limit example listed for IBRANCE and other agents
    Sample oncology and specialty drug entriesNDC/mixed
    REVLIMID ORAL CAPSULE 20 MGDRUG TIER = NF; Requirements / Limits = PA; ONC; S; QL (21 per 1 day)
    REVLIMID ORAL CAPSULE 25 MGDRUG TIER = NF; Requirements / Limits = PA; ONC; S; QL (21 per 28 days)
    REVUFORJ ORAL TABLET 110 MGDRUG TIER = NF; Requirements / Limits = PA; ONC; TD; S
    Venetoclax entries with QLNDC/mixed
    VENCLEXTA ORAL TABLET 100 MGDRUG TIER = NF; Requirements / Limits = PA; ONC; S; QL (6 per 1 day)
    VENCLEXTA ORAL TABLET 50 MGDRUG TIER = NF; Requirements / Limits = PA; ONC; S; QL (1 per 1 day)
    Representative QL examples
    Nystatin oral suspensionQL = 480 per 30 days
    VIVJOA oral capsule 150 mgQL = 18 per 84 days
    Formulary noteQuantity limits are shown as amount per time period (e.g., per 30 days or per 84 days)
    Quantity limit examples (period formats)
    Example per-day limits1 per 1 day (common for some specialty injectables and tablets)
    Example higher daily limits3 per 1 day (selected oncology or stimulant formulations)
    Per-period example21 per 28 days (example listed for IBRANCE)
    VITRAKVI QL example
    VITRAKVI oral solution 20 mg/mLQL = 10 per 1 day
    Specialty designationVITRAKVI entries include PA and specialty program flags where applicable
    Unit guidanceLimit applies to solution units (mg/mL) as listed
    Gabapentin QL example
    Gabapentin oral solution 250 mg/5 mLQL = 72 per 1 day
    Gabapentin tablets (examples)600 mg QL = 6 per 1 day; 800 mg QL = 4 per 1 day
    NEURONTIN oral capsule 100/300 mgQL = 12 per 1 day
    Representative quantity limits across anticonvulsant and other products
    NEURONTIN (oral capsule 100/300 mg)QL = 12 per 1 day
    LYRICA (capsules vary by strength)QL varies by strength: 6, 4, 3, 2 per 1 day
    VIMPAT oral solution 10 mg/mLQL = 40 per 1 day
    ZUBSOLV sublingual tabletQL range = 1–12 per 1 day depending on strength
    Quantity limits examples including sodium oxybate and SPRAVATO
    Sodium oxybate (XYREM/XYWAV) oral solutionQL = 18 per 1 day
    SPRAVATO nasal sprayQL = 4 per 7 days (56 mg strength); QL = 6 per 7 days (84 mg strength)
    WAKIXQL = 2 per 1 day

    Quantity Limits (QL) — Specific Examples

    nystatin oral suspension QL
    Nystatin oral suspensionQL = 480 per 30 days
    Formulary tierDrug Tier = 2 as listed in formulary table
    Unit detail100,000 unit/mL suspension specification shown in formulary
    VIVJOA QL
    VIVJOA oral capsule 150 mgQL = 18 (per 84 days)
    Requirement flagsPA required; Drug Tier = NF
    Period formatQL expressed as per 84 days in formulary table
    IBRANCE QL
    IBRANCE (palbociclib)QL = 21 per 28 days
    Requirement flagsPA; ONC; S indicated in formulary table
    Dose pack noteListed for multiple capsule strengths with same QL period
    KOSELUGO QL
    KOSELUGO oral capsule 10 mgQL = 8 per 1 day
    Other strengths25 mg QL = 4 per 1 day; sprinkle form QL = 2 per 1 day
    Requirement flagsPA; ONC; S as noted
    LYNPARZA QL
    LYNPARZA (olaparib)QL = 4 per 1 day
    Requirement flagsPA; ONC; S where listed
    Dose formsMultiple tablet strengths share same QL per day
    REVLIMID QL
    REVLIMID oral capsule 20 mgQL = 21 (periods vary by pack; example shows 21 per 1 day or per 28 days where specified)
    Requirement flagsPA; ONC; S noted in formulary entries
    Pack variationsDifferent capsule strengths/packs have QL expressed per day or per 28 days as listed
    VITRAKVI ORAL SOLUTION QL
    VITRAKVI oral solution 20 mg/mLQL = 10 per 1 day
    Requirement flagsPA; ONC or specialty flags appear where applicable
    Unit applicabilityLimit applies to solution concentration (mg/mL) as listed
    gabapentin oral solution QL
    Gabapentin oral solution 250 mg/5 mLQL = 72 per 1 day
    Gabapentin oral tablet 600 mgQL = 6 per 1 day
    Gabapentin oral tablet 800 mgQL = 4 per 1 day
    gabapentin oral solution QL (duplicate)
    (Duplicate) Gabapentin oral solution 250 mg/5 mLQL = 72 per 1 day
    Context noteDuplicate entry mirrors formulary listing for solution strength
    Reference strengthsSolution and multiple tablet strengths listed with respective QLs
    gabapentin oral tablet 600 mg QL
    Gabapentin oral tablet 600 mgQL = 6 per 1 day
    Gabapentin oral tablet 800 mgQL = 4 per 1 day
    NEURONTIN capsule referenceNEURONTIN formulations have separate QLs (see capsules and solution listings)
    gabapentin oral tablet 800 mg QL
    Gabapentin oral tablet 800 mgQL = 4 per 1 day
    Related formulationsExtended-release and other formulations may have PA and different QLs
    Formulary tierDrug Tier indicated in table for each strength
    NEURONTIN QL
    NEURONTIN oral capsule 100/300 mgQL = 12 per 1 day
    Requirement flagsPA indicated for many NEURONTIN entries
    Formulation noteNEURONTIN solution and tablets have separate QLs as listed
    LYRICA QL by strength
    LYRICA oral capsule (various strengths)QL varies by strength: 6, 4, 3, 2 per 1 day
    Oral solutionLYRICA oral solution 20 mg/mL QL = 30 per 1 day (listed separately)
    Requirement flagsPA applies to several LYRICA strengths
    NAYZILAM QL
    NAYZILAM nasal spray 5 mgQL = 2 per 30 days
    Requirement flagsPA; NP indicated in formulary entry
    Pack/strength noteDose per spray 0.1 mL as listed in formulary
    VIMPAT oral solution QL
    VIMPAT oral solution 10 mg/mLQL = 40 per 1 day
    VIMPAT oral tablet (100 mg)QL = 4 per 1 day
    Other tablet strengthsTablets 150/200 mg QL = 2 per 1 day; 50 mg QL = 8 per 1 day
    VIMPAT oral tablet QL
    VIMPAT oral tablet (100 mg)QL = 4 per 1 day
    Requirement flagsPA indicated for tablet formulations
    Dose variationsHigher or lower tablet strengths have different QLs as listed
    VALTOCO QL
    VALTOCO nasal sprayQL = 5 per 30 days
    Formulary noteValtoco entry lists QL period as per 30 days
    Use contextDevice/spray count corresponds to listed QL
    NUCYNTA ER 50 mg QL
    NUCYNTA ER 50 mg (extended release)QL = 4 per 1 day
    NUCYNTA ER 100/150/200/250 mgQL = 2 per 1 day
    Requirement flagsPA listed for NUCYNTA ER entries
    NUCYNTA ER higher-strength QL
    NUCYNTA ER higher strengths (100/150/200/250 mg)QL = 2 per 1 day
    Formulary flagsPA and QL noted for extended-release entries
    Related immediate-releaseImmediate-release NUCYNTA has separate NP/OP/QL flags
    ZUBSOLV QL range
    ZUBSOLV sublingual tablet (various strengths)QL range = 1–12 per 1 day depending on strength
    Strength-specific examplesLower-strength packs QL = 12 per 1 day; higher-strength QL = 1 per 1 day
    Program flagsPA/NP flags may apply to some formulations
    Tramadol 25 mg QL
    Tramadol oral tablet 25 mgQL = 16 per 1 day
    Tramadol oral tablet 50 mgQL = 8 per 1 day
    Age limit noteSome tramadol entries include AL (Min 12 Years)
    Tramadol 50 mg QL
    Tramadol oral tablet 50 mgQL = 8 per 1 day
    Related strengthsOther tramadol strengths list QLs and PA/AL flags as shown
    Formulary tierSome tramadol strengths are NF or tiered
    dextroamphetamine sulfate QL range
    Dextroamphetamine sulfate tabletsQL = 2–4 per 1 day depending on strength
    Formulation noteExtended-release formulations may have different QLs (often 1–2 per day)
    Requirement flagsSome strengths require PA
    diazepam formulations QL
    Diazepam formulations (various)QL = 4–40 per 1 day or NP depending on formulation
    ExamplesDiazepam oral tablet 10 mg QL = 4 per 1 day; diazepam oral solution QL = 40 per 1 day
    Program flagsSome diazepam formulations noted NP or other program edits
    DYANAVEL XR QL examples
    DYANAVEL XR and related formulationsPA required; QL = 1–8 per 1 day depending on formulation
    Formulation examplesXR oral suspension QL = 8 per 1 day; tablet forms QL = 1 per 1 day for some strengths
    Requirement flagsPA and QL shown in formulary entries
    EXXUA QL (PA)
    EXXUA oral tablet extended releaseQL = 1 per 1 day (PA required)
    Requirement flagsPA indicated alongside QL in formulary listing
    Use noteExtended-release formulation limited to one tablet per day per QL
    methylphenidate QL variations
    Methylphenidate productsQL values vary by formulation (examples: 1–4 per 1 day); some formulations require PA
    Chewable/tablet examplesChewable and extended-release strengths listed with specific per-day QLs
    Program flagsCertain high-dose ER packs marked PA; QL shown per day
    SODIUM OXYBATE QL
    Sodium oxybate (XYREM/XYWAV) oral solutionQL = 18 per 1 day
    Requirement flagsPA; S noted in formulary entry
    Unit detailSolution concentration 500 mg/mL as listed
    SPRAVATO QL examples
    SPRAVATO nasal spray (56 mg)QL = 4 per 7 days
    SPRAVATO nasal spray (84 mg)QL = 6 per 7 days
    Requirement flagsPA indicated for SPRAVATO entries
    WAKIX QL
    WAKIX oral tabletQL = 2 per 1 day
    Requirement flagsPA; S noted for WAKIX in formulary
    Dose strengthsMultiple tablet strengths listed with same QL
    VYVANSE QL
    VYVANSE oral capsule/tabletQL = 1–2 per 1 day depending on strength
    Requirement flagsPA indicated for many VYVANSE strengths
    Chewable/tablet notesChewable forms may have different per-day QLs (1–2)
    Multiple representative QL examples
    Sample QL formatsExamples across products: 1 per 1 day; 12 per 28 days; 4 per 1 day; 1 per 28 days
    ContextVarious specialty and neurologic products use per-day or per-period QLs as shown
    DocumentationPrescriptions must match dose/pack size consistent with listed QL
    ELIQUIS 30-day start QL
    ELIQUIS DVT-PE TREAT 30D START (74 tabs)QL = 74 per 30 days
    Requirement flagsENH noted; QL expressed as 74 per 30 days for dose pack
    Pack detailDose pack counts correspond to listed QL for initiation pack
    rivaroxaban oral suspension QL
    Rivaroxaban oral suspension for reconstitution 1 mg/mLQL = 20 per 1 day
    Requirement flagsPA; ENH; AL (Min 18 Years) noted for suspension
    Formulation noteSuspension QL differs from tablet QLs as listed
    XARELTO dose pack QL
    XARELTO DVT-PE TREAT 30D START (dose pack)QL = 51 per 30 days
    Requirement flagsENH; QL shown for 30-day start dose pack
    Pack compositionDose pack composition reflected in the 51-tab QL
    phytonadione 5 mg QL
    Phytonadione (vitamin K1) oral tablet 5 mgQL = 3 per 30 days
    Formulary tierListed with standard formulary tiering in table
    Use noteSmall per-month QL reflects occasional use scenarios

    Step Therapy / Therapeutic Direction

    Policy PointSummary / Action
    Step therapy (ST)
    If ST applies, the member must try specified alternate drug(s) first; if alternatives have not been tried, prior approval (PA) is required before the medicine will be covered at the preferred copay/coinsurance.
    FlagImplication
    TD (Therapeutic Direction)
    Indicates therapeutic-direction or step/pathway constraints for some agents; may require trial of specific therapies or clinical pathway adherence prior to coverage.
    Flag / AreaImplication for CNS / Neurology Agents
    NP (Non-Preferred) and program flags
    Several CNS/neurology products are annotated with NP or other program flags (e.g., BRIVIACT = PA; NP; QL), indicating special program handling or additional requirements (such as PA or step edits) before coverage.
    AnnotationOperational meaning
    NP / Nonpreferred annotations
    Products annotated NP alongside PA or QL imply step edits or non-preferred pathways — prescribers may need to document prior trials of preferred agents or obtain PA for NP products.
    FlagPossible implication
    ENH / PREV / NP
    Entries marked ENH or PREV or NP may imply enhanced review or preventive pathway requirements; explicit step sequences are not detailed and may require PA or additional documentation.
    Product / FlagStep therapy note
    TRINTELLIX; zolpidem extended-release formulations
    Listed with ST (step therapy) — these products are subject to step therapy requirements before coverage at preferred cost share.
    FlagAction required
    S (Specialty / Site)
    'S' indicates specialty designation or special routing; follow the payer's specialty routing and step therapy rules where 'S' is present (may require specialty pharmacy dispense and PA).
    Product / FormulationRequirements / Limits
    rivaroxaban oral suspension for reconstitution 1 mg/ml
    Requirements / Limits = PA; ENH; QL (20 per 1 day); AL (Min 18 Years) — enhanced review and prior authorization required prior to coverage.
    FlagInterpretation
    ENH / PREV indicators
    'ENH' or 'PREV' flags may indicate enhanced review or preventive coverage pathways; although explicit step sequences are not provided, these flags signal additional review requirements when present.
    Step Therapy

    Follow TD sequencing or secure authorization

    TD (therapeutic direction) flags on some entries suggest sequencing or step requirements may apply; follow indicated therapeutic‑direction guidance or obtain authorization if sequencing requirements are unmet.

    Documentation Required

    Adhere to NP/program routing for CNS/neurology drugs

    Some CNS/neurology drugs carry NP or other program flags indicating special handling; when these flags appear, providers should follow the program routing and submit required documentation.

    Step Therapy

    Try preferred alternatives or provide PA for NP/step edits

    Products annotated with NP or PA; NP; QL (for example perampanel) imply step edits or non‑preferred pathways — try preferred alternatives or obtain prior approval with supporting clinical rationale.

    Note
    Note
    Note

    Specialty Pharmacy & Site Restrictions

    Note

    Fill specialty/oncology medicines at specialty pharmacy

    Specialty and oncology medicines must be filled at a specialty pharmacy; benefits and routing may differ from retail pharmacy coverage and specialty dispensing requirements must be followed.

    Billing Rule

    Observe site‑of‑care restrictions for S‑flagged injectables

    Some injectable or infusion products are flagged 'S' for site restrictions; these may require administration in infusion center, clinic, or hospital outpatient settings per the formulary entry.

    Note

    Comply with OP/outpatient site restrictions when shown

    OP or outpatient flags indicate site or outpatient program limits for particular formulations; follow the OP designation when present on the product line.

    Billing Rule

    Use specialty pharmacy/infusion center routing for S‑designated products

    Specialty products and certain neurologic injectables annotated 'S' require specialty pharmacy processing and may have specific quantity‑limit periods or administration site requirements.

    Terminology & Abbreviations

    Specialty medicine definition
    Specialty medicine definitionMedicines usually prescribed by specialists for chronic/complex diseases; often require specialty pharmacy fill and may have different benefit coverage
    Specialty fill requirementPrescriptions for specialty medicines must be filled at a specialty pharmacy as noted in the formulary guidance
    Benefit noteSpecialty medicines may be covered under a different benefit than retail medicines
    Abbreviations — PA / ST / QL / AL / NP / OTC
    PAPrior Authorization — Plan requires approval before coverage
    QLQuantity Limit — maximum allowed quantity per specified time period
    STStep Therapy — require trial of specified alternate drugs before coverage at preferred cost share
    PA definition
    PA (Prior Authorization)PA indicates the drug requires prior authorization before coverage
    Clinical purposePA is used to confirm coverage criteria are met for plan benefits
    Denial riskFailure to obtain PA may result in the drug not being covered
    ONC definition
    ONC (Oncology program flag)ONC flags drugs managed under oncology-specific coverage programs
    ImplicationONC entries often include PA, S, or TD flags and specific QLs
    Use caseApply oncology program criteria when ONC is present on formulary line
    S definition
    S (Specialty)S denotes specialty designation or site-of-care restriction (e.g., specialty pharmacy or infusion center)
    Site implicationsProducts marked S may require specialty pharmacy fill or administration at infusion/clinic sites
    Related flagsS often appears with PA and QL in formulary entries
    TD definition
    TD (Therapeutic direction)TD denotes therapeutic direction/step-therapy or clinical pathway constraints
    ApplicationTD may indicate required sequencing or clinical criteria for oncology or specialty agents
    AssociationTD commonly appears with PA and ONC flags in formulary entries
    QL definition
    QL (Quantity Limit)Numeric quantity limit with time period (e.g., '72 per 1 day' or '21 per 28 days')
    EnforcementClaims exceeding QL may be reviewed for medical necessity and require documentation
    FormatsQL periods appear as per 1 day, per 7 days, per 28 days, per 30 days, per 84 days, etc.
    PA/ONC/QL shorthand
    PA shorthandPA = Prior Authorization
    ONC shorthandONC = Oncology program flag
    QL shorthandQL = Quantity Limit

    Background & Scope

    Specialty medicines are typically prescribed for chronic or complex conditions and often require dedicated management and dispensing through a specialty pharmacy. These products may be subject to different benefit rules and additional program requirements (for example, prior authorization, oncology program review, site-of-care restrictions) compared with standard retail pharmacy fills.

    This policy governs the HealthPartners 2026 drug formulary and associated pharmacy benefit rules. It establishes that coverage is subject to plan rules and formulary edits and that many drugs are covered only when specified conditions are met — for example, when prior authorization (PA) requirements, step therapy (ST) sequencing, quantity limits (QL), or age limits (AL) are satisfied. The document also outlines specialty drug handling: certain specialty and oncology medicines must be dispensed via specialty pharmacy and may have different site-of-care or benefit provisions.

    Revision History